FOR HEALTHCARE PROFESSIONALS ONLY

This website is a global information resource. It is intended for healthcare professionals only outside of the United States of America (US) who are interested in information on Foundation Medicine®. This site is not intended to provide medical advice and/or treatment guidance. If you are a US healthcare professional click here.

This site is produced by Roche as a partner of Roche Foundation Medicine.

!
We use cookies to help provide you with a better service. You can change your cookie settings at any time. Otherwise, we will assume you're OK to continue.
×
Menu
Close
Alt

Kako naručiti Foundation Medicine uslugu

Proces naručivanja

Jednostavan, lako dostupan proces narudžbe

Foundation Medicine usluga se realizira u roku od 14 do 20  dana od trenutka prijema uzorka u našoj laboratoriji.

Potrebno je da se bolesnik posavjetuje sa njegovim nadležnim ljekarom, onkologom ili hematologom, da li je jedan od tri testa optimalan izbor za njega.

Nadležni ljekar može pomoći pri donošenju odluke o Foundation Medicine genskom profiliranju, ali sve tehničke detalje oko provođenja testiranja dogovarate sa zvaničnim distributerima, ovlaštenim pružaocima usluge u BiH:

  • DIAGGEN d.o.o.
    Sagrdžije 82
    Sarajevo
    tel. +387 60 344 3001

  • Zdravstvena ustanova S.Tetik
    Patrijarha Arsenija Čarnojevića 2b
    Banja Luka
    tel. +387 51 430 888
    www.s-tetik.com

Naručivanje Foundation Medicine usluge

Uputstva za uzorak

Formalin-fixed paraffin-embedded (FFPE) specimens, including cut slide specimens, are acceptable4
Instrukcije za pripremu uzorka

Two 8.5 mL peripheral
blood specimens5
 
Instrukcije za pripremu uzorka

Peripheral blood, bone marrow aspirate or FFPE tissue specimens may be used with ≥20% tumour cell content6
Instrukcije za pripremu uzorka
PD-L1 dopunski test

PD-L1, imunohistohemijska analiza se može dodatno naručiti

PD-L1 status (determiniran uz pomoć imunohistohemijske analize; IHC) ne korelira sa mutacijskim tumorskim opterećenjem (eng. tumour mutational burden (TMB). Imajući navedeno u vidu, PD-L1 testiranje i TMB status mogu dati sveobuhvatniju informaciju prilikom donošenja odluke za primjenu kancer-imunoterapije.7–9 PD-L1 testiranje se može naručiti kao dodatni test.
References
  1. FoundationOne®CDx Technical Specifications, 2018. Available at: www.rochefoundationmedicine.com/f1cdxtech (Accessed March 2019).
  2. FoundationOne®Liquid Technical Specifications, 2018. Available at: https://www.foundationmedicine.com/genomic-testing/foundation-one-liquid (Accessed March 2019).
  3. FoundationOne®Heme Technical Specifications, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed March 2019).
  4. FoundationOne®CDx Specimen Instructions, 2018. Available at: www.rochefoundationmedicine.com/specimen (Accessed March 2019).
  5. FoundationOne®Liquid Specimen Instructions 2018. Available at: https://www.foundationmedicine.com/genomic-testing/foundation-one-liquid (Accessed March 2019).
  6. FoundationOne®Heme Specimen Instructions, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed March 2019).
  7. Kamzi S. Presented at ESMO Immuno Oncology Congress 2017; Geneva, Switzerland: Poster no. 35P.
  8. Rizvi H et al. J Clin Oncol 2018; 36: 633–641.
  9. Hellmann MD et al. Cancer Cell 2018; 33: 843–852.e4.